BMC Medicine Time to First Decision: 3-Day Median

BMC Medicine submissions run through the Springer Nature submission system. The status labels you see in your author account may differ from the stage names below, which describe the stages of BMC's editorial process.

"With Editor" is the initial-screen stage. After the initial quality check, an editor decides whether the paper is suitable for peer review. The editor weighs scope fit (BMC Medicine prioritizes broad-relevance medical research), reporting-guideline compliance (CONSORT for RCTs, STROBE for observational studies, PRISMA for systematic reviews, ARRIVE for animal studies), and ethical-approval documentation. The journal does not publish a desk-rejection rate, but a 3-day median to first decision means many submissions are decided at this stage, commonly on scope or reporting grounds.

"Under Review" means the paper has passed editorial assessment and is with independent peer reviewers. BMC's peer review policy says typically two or more experts evaluate each manuscript. If first-choice reviewers decline, recruitment can extend the wait by 1-2 weeks.

"Reviews Completed" means the reviewer reports have arrived and the Editor is weighing them. This is usually a short stage (1-2 weeks). If the Editor asks for changes, plan the point-by-point response for BMC Medicine as a public document from the first draft.

"Decision in Process" means the Editor has decided and the formal decision letter is being prepared. This is days, not weeks.

If your paper sits at the editor stage for more than 3 weeks, that is well beyond the journal's reported 3-day median to first decision. After 4 weeks, a polite inquiry is appropriate.

Three structural factors drive the longer timeline for papers that go to external review:

Reporting-guideline compliance checks. BMC's editorial policies say the reporting checklist must be completed before peer review and made available to the editors and reviewers, and BMC strongly encourages CONSORT, PRISMA, STROBE, ARRIVE and other checklists. Papers that complete checklists with "see Methods" or "N/A" can be returned for revision, which adds time before peer review begins.

Reviewer recruitment for clinical specificity. BMC Medicine covers all of clinical medicine plus public health and global health. Reviewer pools for narrower subfields (e.g., specific tropical diseases, rare cancers, niche preventive interventions) can take longer to recruit.

Submission volume. Busy periods (post-conference cycles, January submissions) can lengthen the wait at the initial screen.

If your paper has been at "Under Review" for 6-10 weeks, that is normal. The more useful calibration:

• Under Review less than 4 weeks: Reviewers may still be confirming or starting reports. No read.

• 4-8 weeks: Reports often arrive in this window.

• 8-12 weeks: Decision is imminent if reports are in.

• 12+ weeks: Reviewer recruitment difficulty or split reviewer opinions. Inquiry appropriate.

Wait at least 12-14 weeks from submission before contacting the BMC Medicine editorial office. When you do:

• Contact the editorial office using the address in your submission confirmation

• Reference your manuscript ID

• Keep the message brief: request a status update, note when you submitted

One follow-up per 4-week interval after the 14-week mark is reasonable. The editorial office can prompt unresponsive reviewers but cannot bypass them. For specialized clinical topics, the office may explain the delay and provide an updated estimate.

• Reject: Usually with reviewer comments. BMC Medicine editors weigh reviewer judgment heavily; a clean reject typically reflects substantive methodological or scope objections.

• Major revision: Most common at BMC Medicine. Expect requests to clarify methods, expand limitations, complete reporting checklists thoroughly, or address specific reviewer questions.

• Minor revision: Common for well-prepared manuscripts; usually 2-4 weeks turnaround for the second round.

• Accept: Possible but uncommon as a first response.

Before submitting a revision with significant new analyses, a BMC Medicine submission readiness check can assess whether the response addresses the reviewers' core methodological concerns.

Of the medical research manuscripts our team reviewed before BMC Medicine submission, three named rejection patterns account for the bulk of editorial returns. Editors at BMC Medicine consistently reject papers on these three patterns at the initial screen. The hidden filter authors most often miss is whether the paper reads as broad-relevance medicine or specialty medicine.

Editorial culture at BMC Medicine demands that the public-health or general-medicine relevance be explicit and the reporting-checklist compliance be complete.

Reporting checklists completed with "see Methods" instead of specific page citations. BMC's editorial policies require the reporting checklist for your study type (CONSORT, PRISMA, STROBE, ARRIVE and others) to be completed before peer review and made available to the editors and reviewers. We observe that papers completing checklists with generic "see Methods" or "N/A" entries generate editorial returns at the initial-screen stage. Papers that map each checklist item to a specific page clear this screen more easily and move to peer review.

Data availability statements that give no reason or conditions. BMC's editorial policies require every manuscript to include an "Availability of data and materials" statement saying where the supporting data can be found, and the research article instructions list "available from the corresponding author on reasonable request" among the accepted statement forms. Where data cannot be shared openly, the statement should give the reason, and BMC notes that on some journals the editors may decline further consideration if restrictions are found to be unduly prohibitive. We see authors include a one-line "data available from the corresponding author on reasonable request" because their institutional or funder agreement does not require full deposit.

Papers that proactively address data availability with a deposit URL, repository identifier, or a detailed explanation of restrictions give editors less to query and tend to move faster.

Manuscripts framed for a sub-specialty audience without broader medical relevance. BMC Medicine's scope is broad medicine: papers should be relevant to general physicians, public-health practitioners, or health-systems researchers, not only to a narrow sub-specialty.

We observe that authors with strong sub-specialty papers (e.g., niche oncology subtypes, rare neurological conditions, specialty-specific surgical techniques) target BMC Medicine because of its broad readership and high impact factor, but editors can redirect these papers to BMC sub-specialty journals (BMC Cancer, BMC Neurology, BMC Surgery) through BMC's manuscript transfer service, which carries the manuscript files and any reviewer comments across.

A BMC Medicine submission readiness check can identify whether the paper's broad-medicine relevance is sufficient before submission.